Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Choroideremia (CHM) is an X-linked chorioretinal dystrophy that is caused by mutations within a single gene, CHM. Currently no effective treatment exists for these patients. Since over 30% of patients harbour nonsense mutations in CHM, nonsense suppression therapy using translational readthrough inducing drugs may provide functional rescue of REP1, thus attenuating progressive sight loss. Here, we employed two CHM model systems to systematically test the efficacy and safety of ataluren (PTC124) and its novel analog PTC-414: (1) the chmru848zebrafish, the only nonsense mutation animal model of CHM harbouring a TAA nonsense mutation, and (2) a primary human fibroblast cell line from a CHM patient harbouring a TAG nonsense mutation. PTC124 or PTC-414 treatment of chmru848embryos led to a ∼2.0-fold increase in survival, prevented the onset of retinal degeneration with reduced oxidative stress and apoptosis, increased rep1 protein by 23.1% (PTC124) and 17.2% (PTC-414) and restored biochemical function as confirmed through in vitro prenylation assays (98 ± 2% [PTC124] and 68 ± 5% [PTC-414]). In CHMY42X/y fibroblasts, there was a recovery of prenylation activity following treatment with either PTC124 (42 ± 5%) or PTC-414 (36 ± 11%), although an increase in REP1 protein was not detected in these cells, in contrast to the zebrafish model. This comprehensive study on the use of PTC124 and PTC-414 as successful nonsense suppression agents for the treatment of CHM highlights the translational potential of these drugs for inherited retinal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of plasmalogen lipids in health and disease
Braverman, N. E., & Moser, A. B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.05.008 · Cited by 1,082 · cited 1×
“Elevated plasmalogens (which are membrane glycerophospholipids that play a role in the structural properties of cell membranes, including signalling, fission, and fusion, and oxidative stress) [49], and nervonic acid (a monounsaturated omega-9 acid, important in the biosynthesis of neuronal myelin, and found in sphing…”
BackgroundCalvo, S. E., Pagliarini, D. J., & Mootha, V. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810916106 · Cited by 914 · cited 1×
“The human CHM uORF may have impacted on protein expression, as uORFs have been found to lower protein levels by 30– 80% [29].”
BackgroundMacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 1×
“The first Phase I–II viral gene therapy clinical trial involving six patients with CHM was reported to be safe and well tolerated, with a >2- and 4-line improvement in visual acuity in two patients following treatment with the AAV2-REP1 vector [45].”
Self-citationUpstream Open Reading Frames as Regulators of mRNA Translation
Morris, D. R., & Geballe, A. P. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8635-8642.2000 · Cited by 736
Gene Expression Regulation by Upstream Open Reading Frames and Human Disease
Barbosa, C., Peixeiro, I., & Romão, L. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003529 · Cited by 525 · cited 12×
“Due to the downstream AUG position in the CHM patient, mRNA transcripts are likely to be susceptible to NMD resulting in the lower baseline levels seen in the fibroblasts.”
BackgroundInfluentialCereso, N., Pequignot, M. O., Robert, L., Becker, F., De Luca, V., Nabholz, N., Rigau, V., De Vos, J., Hamel, C. P., & Kalatzis, V. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.11 · Cited by 72
Self-citation
Cited by
Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 257
Gene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Gene Therapy in Retinal Dystrophies
Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225722 · Cited by 107
Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80
Metadata
- Authors
- Moosajee, M., Tracey-White, D., Smart, M., Weetall, M., Torriano, S., Kalatzis, V., da Cruz, L., Coffey, P., Webster, A. R., & Welch, E.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-21
- Volume
- 25
- Issue
- 16
- Pages
- 3416-3431
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2460429062
- Cited by
- 77
- References
- 6
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.